Epidemiologic monitoring of prenatal screening for neural tube defects and Down syndrome

Clinics in Laboratory Medicine

Volumn 23, Issue 2, 2003, Pages 531-551

  Knight, George J ^a   Palomaki, Glenn E ^a  

^a FOUNDATION FOR BLOOD RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODY WEIGHT; DOWN SYNDROME; EPIDEMIOLOGY; GESTATIONAL AGE; HUMAN; MATERNAL AGE; NEURAL TUBE DEFECT; PRENATAL SCREENING; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW;

EID: 0038786849     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(03)00023-4     Document Type: Review

References (22)

1. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992;327(9):588-93.
2. Haddow JE, Palomaki GE, Knight GJ, Cunningham CG, Lustig LS, Boyd P. Reducing the need for amniocentesis in women age 35 years of age and older with serum markers for screening. N Engl J Med 1994;330(16):1114-8.
3. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998;338(14):955-61.
4. Westgard JO, Klee GG. Quality management. In: Burtis CA, Ashwood ER, editors. Tietz textbook of clinical chemistry. 2nd edition. Philadelphia: W.B. Saunders Co.; 1993. p. 548-92.
5. Wald N, Leck I, editors. Antenatal and neonatal screening. 2nd edition. Oxford (UK): Oxford University Press; 2000. p. xii.
6. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of the UK collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet 1977;1(8026):1323-32.
7. Variables which influence the levels of AFP, uE3, and hCG and/or risk for down syndrome. In: Haddow JE, Palomaki GE, Knight GJ, Canick JA. Prenatal screening for major fetal disorders. Vol. II: Down syndrome. Scarborough, ME: Foundation for Blood Research; 1998.
8. Wald NJ, Cuckle HS, Densem J, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297(6655):883-7.
9. National Institute of Child Health and Human Development. The quality control of alpha-fetoprotein reagents and assay for the antenatal screening and diagnosis of open neural tube defects. Clin Chem Acta 1980;105(1):9-24.
10. FBR/CAP Maternal Screening Survey: Participant Summary Report. FP-A 2000. Northfield (IL): College of American Pathologists; 2002.
11. Knight GJ, Palomaki GE, Haddow JE. Maternal serum alpha-fetoprotein: a problem with a test kit. N Engl J Med 1986;314(8):516.
12. Knight GJ, Palomaki GE, Haddow JE. Assessing reliability of AFP test kits. Contemp Ob Gyn 1987;30:37-52.
13. Knight GJ, Haddow JA, Palomaki GE, Haddow JE. Selection and validation of alpha-fetoprotein assay kits for Down syndrome. Am J Obstet Gynecol 1987;156(6):1557-9.
14. Knight GJ, Palomaki GE. Epidemiologic monitoring and quality control of prenatal screening. In: Sturgeon CM, Seth J, Middle JG, Halloran SP, editors. Proceedings of the UK NEQAS meeting. London: Association of Clinical Biochemists Ltd. 1995;1:120-6.
15. Knight GJ. Quality assessment of a prenatal screening program. Early Hum Dev 1996;47(Suppl):S49-53.
16. Baumgarten A. Racial difference and biological significance of maternal serum alpha fetoprotein. Lancet 1986;2(8506):573.
17. Centers for Disease Control. Vital Health Statistics 2000 Natality Data Set [database on CD-ROM]. Series 21, Number 14. Hyattvill (MD): Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; April 2002.
18. Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 1996;16(12):1115-9.
19. Knight GJ, Palomaki GE, Haddow JE. Use of maternal serum alpha-fetoprotein measurements to screen for Down's syndrome. Clin Obstet Gynecol 1988;31(2):306-27.
20. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352(9125):343-6.
21. Spencer K, Spencer CE, Power M, Moakcs A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies: report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 2000;107(10):1271-5.
22. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997;17(9):821-9.